Pamela Strode has been promoted to vice president of regulatory affairs and quality assurance at Epizyme, Inc., a clinical stage biopharma company developing epigenetic therapies for cancer. Ms. Strode will report to Epizyme’s president and chief executive officer, Robert Bazemore and will oversee all activities related to global regulatory strategy, including interactions with regulatory authorities regarding tazemetostat and global filings.   “This next year will be transformational for Epiz...